ClinicalTrials.gg
RecruitingNCT07617506Updated Aug 24, 2026

Neural Basis of Human Working Memory

An interventional study of Neurocognitive Tasks and Ripple Neuromed Summit System in Memory Disorders, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2025, registered May 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This ClinicalTrials.gov entry corresponds to the Neural Basis of Human Working Memory protocol approved under Vanderbilt University Medical Center IRB #251231.

This study investigates the neural activity underlying human working memory, via local field potential changes (macro level) and/or single neuronal spiking changes (micro level) from depth electrodes placed for invasive seizure monitoring. Subjects will complete neurocognitive tasks while neural recordings are collected. Some patients will complete neurocognitive tasks while stimulation is applied via depth electrodes. Further understanding the neural activity changes underlying normal and impaired working memory may help to identify novel diagnostic methods and treatments for impaired working memory and may support the use of stimulation for treatment of memory disorders.

02

Conditions studied

  • Memory Disorders

Browse trials for

Keywords

  • Neural stimulation
  • Memory disorders
  • Working Memory
  • Stereo Electroencephalography (SEEG)
03

In context

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

This study's planned enrollment of 100 is above the median of 72 across 298 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 833 studies on the registry; 155 are open to participants now.

Of its 125 completed or terminated interventional studies of FDA-regulated products, 92 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing SEEG monitoring at Vanderbilt University Medical Center
  • Age >18
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Age \<18
  • Not able to complete questionnaires (unable to comprehend instructions or follow directions)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Epilepsy patients

    All participants will be patients with medically refractory epilepsy who have undergone depth electrode placement for stereo EEG monitoring for seizure localization. Participants will complete working memory tasks and EEG recordings will be concurrently collected from their depth electrodes. Some subjects will undergo macro-micro electrode implantation as a part of their SEEG implantation procedure for the purpose of EEG macro (local activity) and micro (single-unit) recordings. Some subjects will complete working memory tasks with stimulation applied during task completion.

    Behavioral: Neurocognitive Tasks · Device: Ripple Neuromed Summit System

Interventions

  • BehavioralNeurocognitive Tasks

    Participants complete computerized neurocognitive tasks assessing working memory, response inhibition, decision-making, reward processing, and other related cognitive functions during sEEG monitoring. Tasks may include the stop signal reaction time task, the n-back working memory task, the delayed response task, the match/nonmatch task, the gambling task, the card guessing task, and the emotional stop signal reaction time task. Intracranial neural activity is recorded during task performance, and select tasks may include research electrical stimulation delivered through the implanted sEEG electrodes.

  • DeviceRipple Neuromed Summit System

    Neurophysiology system designed to allow recording of neural signals as well as delivery of neural stimulation. The system is a portable unit which is connected to cables connected to the clinical electrodes. Neurophysiology signals from the electrodes can be recorded, amplified, and processed by the unit. The unit also has the ability to deliver electrical stimulation through the electrodes according to programmed parameters.

06

What researchers measure

Primary outcomes

  1. Local field potential changes in response to working memory tasks

    Local field potential changes are from intracranial neural recordings taken while patients complete spatial working memory tasks. In the manual remember 1 remember 2 task, patients are instructed to hold down a cursor on a central location box colored one color or another on screen, while two boxes in locations sequentially flash on screen. Depending on the central location box color, the patient will drag their cursor to the first or second location box shown, after the central box has disappeared from screen. In the retro remember 1 remember 2 task, the color of the central box color is not shown until both location boxes have flashed onscreen. In the manual version, the central location box color is constant throughout the trial.

    Time frame: During patient's epilepsy monitoring stay, approximately 20-30 minutes

  2. Single unit neuronal spiking changes in response to memory tasks

    Single neuron spiking activity is recorded through SEEG micro neural recordings while patients complete working memory tasks.

    Time frame: During patient's epilepsy monitoring stay, approximately 20-30 minutes

  3. Behavioral performance changes with stimulation

    Bipolar stimulation through pre-selected SEEG electrodes in the prefrontal cortex and surrounding areas will occur during the remember 1 remember 2 working memory tasks. Stimulation will be performed via the Ripple Neuromed Summit system. Stimulation will be tested with each patient prior to task to determine safety and tolerability, while patient is monitored by a neurosurgeon or neurologist.

    Time frame: During patient's epilepsy monitoring stay, approximately 20-30 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 129 non-industry interventional studies with no phase under Memory Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 53. This study's planned 22 months is below that.

Counting every sponsor, half of 138 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jun 1, 2026
StartActual
Jun 4, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617506
Responsible party
Christos Constantinidis (Professor of Biomedical Engineering, Principal Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
Jun 1, 2026
Start date
Jun 4, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Lucas Chang, BS
Contact
lucas.m.chang@vumc.org
615-421-3046
Christos Constantinidis, PhD
Contact
christos.constantinidis.1@Vanderbilt.Edu
+1 (615) 936-2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion